WHO ICTRP trial
The study is to Assess Bioequivalence of Olaparib Tablets in Patients who are…
CTRI/2023/10/059083 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/10/059083 |
|---|---|
| Public title | The study is to Assess Bioequivalence of Olaparib Tablets in Patients who are suffering from Cancer Under Fed Condition. |
| Scientific title | A Randomized, Open-label, Three-Treatment, Three-Period, Three-Sequence, Balanced, Multiple-Dose, Multi-Center, Crossover Study to Assess Bioequivalence of Olaparib Tablets of Intas Pharmaceuticals Limited Compared with Lynparza® in Patients with Solid Tumours Under Fed Condition - Nil |
| Primary sponsor | Intas Pharmaceuticals Limited, India |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | BA/BE |
| Countries | India |
| Conditions | Health Condition 1: C801- Malignant (primary) neoplasm, unspecified |
| Interventions | Intervention1: Olaparib Tablets 150 mg: Intervention Description-Each film-coated tablet contains olaparib 150 mg,Dose Formulation-Tablet,Unit Dose Strength(s)-150 mg,Dosage Level(s) 300 mg (two tablets of 150 mg) taken twice daily… |
| Registration date | Oct 25, 2023 |
| Target size | 18 |
| Secondary IDs | 0389-22,Version: 1.0,Date: 21-Jan-2023 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: